Comparative in Vitro Cellular Data Alone Is Insufficient to Predict Clinical Responses and Guide Choice of BCR-ABL Inhibitor to Treat Imatinib-Resistant Chronic Myeloid Leukemia

被引：0
|
作者：
Laneuville, Pierre [1 ]
DiLea, Clifford [2 ]
Mestan, Juergen [3 ]
Yin, Ophelia [2 ]
Woodman, Richard C. [2 ]
Manley, Paul [3 ]
机构：
[1] McGill Univ, Ctr Hlth, Montreal, PQ, Canada
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Novartis Pharma AG, Basel, Switzerland
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：211 / 211
页数：1
相关论文
共 50 条
  • [31] Imatinib-resistant activation of β-catenin by BCR-ABL in a murine model of chronic myelogenous leukemia stem cells.
    Minami, Yosuke
    Stuart, Scott
    Ikawa, Tomokatsu
    Banno, Asoka
    Hunton, Irina
    Willert, Karl
    Murre, Cornelis
    Jamieson, Catriona
    Wang, Jean Y. J.
    BLOOD, 2006, 108 (11) : 603A - 603A
  • [32] Bestinib, a novel Bcr-Abl inhibitor for Chronic Myeloid Leukemia, inhibits a wide array of Bcr-Abl mutants including imatinib resistant T315I mutant
    Gupta, Pranav
    Yang, Ke
    Wang, Fang
    Wang, Xiaokun
    Kathawala, Rishil J.
    Fu, Liwu
    Chen, Zhe Sheng
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S100 - S100
  • [33] IMPACT OF BCR-ABL MUTATIONS ON RESPONSE TO DASATINIB IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS RESISTANT TO IMATINIB
    Tiribelli, M.
    Latagliata, R.
    Breccia, M.
    Luciano, L.
    Castagnetti, F.
    Gozzini, A.
    Cambrin, G. Rege
    Annunziata, M.
    Stagno, F.
    Pregno, P.
    Albano, F.
    Abruzzese, F.
    Musto, P.
    Sora, F.
    Ferrero, D.
    Montefusco, E.
    Cavazzini, F.
    Binotto, G.
    Fanin, R.
    Pane, F.
    Rosti, G.
    Santini, V.
    Fava, C.
    Alimena, G.
    Vigneri, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 347 - 347
  • [34] Detection of BCR-ABL point mutations in patients with chronic myeloid leukemia (CML) resistant to imatinib.
    Silveira, Rosana A.
    Albuquerque, Dulcineia M.
    Assis, Angela M.
    Ichihara, Edson
    de Souza, Carmino A.
    Costa, Fernando F.
    Delamain, Marcia T.
    Vigorito, Afonso C.
    Lorand-Metze, Irene
    Miranda, Eliana
    Pagnano, Katia B. B.
    BLOOD, 2006, 108 (11) : 289B - 289B
  • [35] RESPONSE TO NILOTINIB IN PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH DIFFERENT BCR-ABL TRANSCRIPT TYPES
    Saglio, S.
    Hughes, T.
    Kim, D. W.
    Hanfstein, B.
    Gottardi, E.
    Branford, S.
    Goh, H.
    Beppu, L.
    Soverini, S.
    Shou, Y.
    Stein, A.
    Woodman, R.
    Kantarjian, H.
    Radich, J.
    Hochhaus, A.
    Martinelli, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 342 - 343
  • [36] Characteristics of BCR–ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients
    YaZhen Qin
    ShanShan Chen
    Bin Jiang
    Qian Jiang
    Hao Jiang
    JinLan Li
    LingDi Li
    YueYun Lai
    YanRong Liu
    XiaoJun Huang
    Annals of Hematology, 2011, 90 : 47 - 52
  • [37] Andrographolide and its potent derivative exhibit anticancer effects against imatinib-resistant chronic myeloid leukemia cells by downregulating the Bcr-Abl oncoprotein
    Liao, Hsin-Chia
    Chou, Yi-Ju
    Lin, Ching-Cheng
    Liu, Sheng-Hung
    Oswita, Audrey
    Huang, Yi-Long
    Wang, Ying-Lien
    Syu, Jia-Ling
    Sun, Chung-Ming
    Leu, Chuen-Miin
    Lin, Chao-Hsiung
    Fu, Shu-Ling
    BIOCHEMICAL PHARMACOLOGY, 2019, 163 : 308 - 320
  • [38] Targeting HSPA8 inhibits proliferation via downregulating BCR-ABL and enhances chemosensitivity in imatinib-resistant chronic myeloid leukemia cells
    Liu, Zhen
    Zheng, Wenlong
    Liu, Yuan
    Zhou, Binghe
    Zhang, Yuqing
    Wang, Fan
    EXPERIMENTAL CELL RESEARCH, 2021, 405 (02)
  • [39] Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
    Jabbour, E.
    Kantarjian, H.
    Jones, D.
    Talpaz, M.
    Bekele, N.
    O'Brien, S.
    Zhou, X.
    Luthra, R.
    Garcia-Manero, G.
    Giles, F.
    Rios, M. B.
    Verstovsek, S.
    Cortes, J.
    LEUKEMIA, 2006, 20 (10) : 1767 - 1773
  • [40] BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.
    Kim, D.
    Saglio, G.
    Martinelli, G.
    Shou, Y.
    Stein, A. M.
    Woodman, R. C.
    Kantarjian, H.
    Hughes, T. P.
    Radich, J. P.
    Hochhaus, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345